Using a pooled, targeted sequencing approach, the team is using the HiSeq to sequence both germline and tumor DNA from children enrolled in high-risk ALL trials, with the goal of finding rare variants that increase a child's risk for developing the disease, act as driver mutations, and affect tumorigenesis.